LUNESTA R Study Of Patients With Insomnia And Co-Morbid Generalized Anxiety Disorder GAD Published In Archives Of General Psychiatry
Sepracor Inc. (Nasdaq: SEPR) announced the publication of a study of LUNESTA tablets in patients with insomnia and co-morbid generalized anxiety disorder (GAD) in the May issue of the Archives of General Psychiatry. This 595-patient study examined the safety and efficacy of LUNESTA co-administered with escitalopram oxalate, which is commonly used in the treatment of anxiety, versus co-administration of escitalopram and placebo in patients with insomnia and co-existing GAD.
High Anxiety?
Right now, about half of all people who take medicine for an anxiety disorder don't get much help from it. And doctors have no definitive way to predict who will, and who won't, benefit from each anti anxiety prescription they write. But a University of Michigan Medical School researcher and his team are working to bring more certainty to how doctors and patients choose anxiety treatments, by probing the connection between brain activity, genetics and medication.
Alcohol Cravings In Response To Negative Emotions Felt More Acutely By Men
Women and men tend to have different types of stress-related psychological disorders. Women have greater rates of depression and some types of anxiety disorders than men, while men have greater rates of alcohol-use disorders than women. A new study of emotional and alcohol-craving responses to stress has found that when men become upset, they are more likely than women to want alcohol.
Lyrica Reduced Pain Of Fibromyalgia In Patients Regardless Of Symptoms Of Anxiety Or Depression
Pfizer's Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study, according to a pooled analysis presented today at the American Academy of Neurology annual meeting.
1 In 5 Iraq And Afghanistan Veterans Suffer From PTSD Or Major Depression
Nearly 20 percent of military service members who have returned from Iraq and Afghanistan -- 300, 000 in all -- report symptoms of post traumatic stress disorder or major depression, yet only slight more than half have sought treatment, according to a new RAND Corporation study.
Memory Manipulation Questioned By Moral Philosopher
Is medicated memory manipulation ethically sound? And perhaps more importantly, who should be charged with the decision to deliver such a treatment: patient or physician? Elisa Hurley, a philosophy professor, is seeking answers to these questions in her research currently underway at The University of Western Ontario.
Alexza Completes Enrollment In Phase 2a Clinical Trial With AZ-002 Staccato R Alprazolam In Panic Disorder Patients
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder.
Improving Anxiety Treatment Through The Help Of Brain Imaging: A Potential Future Treatment Strategy
Wouldn't it be nice if our doctors could predict accurately whether we would respond to a particular medication? This question is important because research studies provide information about how groups of patients tend to respond to treatments, but inevitably, differences among groups of patients with the same diagnosis mean that findings about groups of patients may not apply to individuals from those groups.
Next Pharmaceuticals Announces A New Clinical Study Demonstrating Relora R Significantly Relieves Short-Term Anxiety In Healthy Women
Next Pharmaceuticals announced the results of a six-week, double-blind, placebo-controlled clinical study on Relora conducted on healthy women between the ages of 20 and 50. Relora significantly reduced short-term anxiety compared to the placebo group.
BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety
BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.